Study of Epacadostat (INCB024360) Alone and In Combination With Pembrolizumab (MK-3475) With Chemotherapy and Pembrolizumab Without Chemotherapy in Participants With Advanced Solid Tumors (MK-3475-434)
Sponsor
Merck Sharp & Dohme LLC (Industry)
Overall Status
Completed
CT.gov ID
NCT02862457
Collaborator
(none)
34
7
50.9
Study Details
Study Description
Brief Summary
This is an open-label, non-randomized, Phase I study of epacadostat (INCB024360) alone and in combination with pembrolizumab with chemotherapy and pembrolizumab without chemotherapy in participants with advanced solid tumors. The primary objective of the trial is to evaluate the safety and tolerability of epacadostat administered alone and in combination with pembrolizumab with and without chemotherapy.
With protocol amendment 02 (26-April-2019), treatment with epacadostat was stopped in the "Epacad+Pembro+Cisplatin+Pemetrexed", "Epacad+Pembro+Carboplatin+Pemetrexed", and "Epacad+Pembro+Carboplatin+Paclitaxel" study arms.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Study Design
Study Type:
Interventional
Actual Enrollment
:
34 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Phase I Study of INCB024360 (Epacadostat) Alone, INCB024360 in Combination With Pembrolizumab (MK-3475), and INCB024360 and Pembrolizumab in Combination With Chemotherapy in Patients With Advanced Solid Tumors (KEYNOTE-434)
Actual Study Start Date
:
Aug 23, 2016
Actual Primary Completion Date
:
Nov 20, 2020
Actual Study Completion Date
:
Nov 20, 2020
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Part A Cohort 1: epacadostat 25 mg Participants received 25 mg of epacadostat orally twice daily (BID) alone on Days 1-5 of Cycle 1 (28-day cycle) with a washout on Days 6 and 7. On Day 8 participants received a one-time intravenous (IV) infusion of 200 mg pembrolizumab while continuing to receive 25 mg of epacadostat BID on Days 8-28. For each 21-day cycle thereafter, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and received 25 mg of epacadostat BID on Days 1-21 for up to 35 cycles (approximately 2 years). |
Drug: Epacadostat 25 mg
Oral administration
Other Names:
Biological: pembrolizumab 200 mg
Intravenous (IV) infusion
Other Names:
|
| Experimental: Part A Cohort 1: epacadostat 100 mg Participants received 100 mg of epacadostat orally BID alone on Days 1-5 of Cycle 1 (28-day cycle) with a washout on Days 6 and 7. On Day 8 participants received a one-time IV infusion of 200 mg pembrolizumab while continuing to receive 100 mg of epacadostat BID on Days 8-28. For each 21-day cycle thereafter, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and received 100 mg of epacadostat BID on Days 1-21 for up to 35 cycles (approximately 2 years). |
Drug: Epacadostat 100 mg
Oral administration
Other Names:
Biological: pembrolizumab 200 mg
Intravenous (IV) infusion
Other Names:
|
| Experimental: Part A Cohort 2: epacadostat 25 mg+pembrolizumab For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and received 25 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years). |
Drug: Epacadostat 25 mg
Oral administration
Other Names:
Biological: pembrolizumab 200 mg
Intravenous (IV) infusion
Other Names:
|
| Experimental: Part A Cohort 2: epacadostat 100 mg+pembrolizumab For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and received 100 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years). |
Drug: Epacadostat 100 mg
Oral administration
Other Names:
Biological: pembrolizumab 200 mg
Intravenous (IV) infusion
Other Names:
|
| Experimental: Part B Cohort 1: pembrolizumab+cisplatin+pemetrexed For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and 100 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years). For the first 4 cycles, participants also received a one-time IV infusion of 75 mg/m^2 cisplatin and 500 mg/m^2 pemetrexed on Day 1. Treatment with epacadostat was stopped with protocol amendment 02. |
Drug: Epacadostat 100 mg
Oral administration
Other Names:
Biological: pembrolizumab 200 mg
Intravenous (IV) infusion
Other Names:
Drug: Cisplatin 75 mg/m^2
IV infusion
Other Names:
Drug: Pemetrexed 500 mg/m^2
IV infusion
Other Names:
|
| Experimental: Part B Cohort 2: pembrolizumab+carboplatin+pemetrexed For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and 100 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years). For the first 4 cycles, participants also received a one-time IV infusion of Area Under the Curve (AUC) 5 carboplatin and 500 mg/m^2 pemetrexed on Day 1. Treatment with epacadostat was stopped with protocol amendment 02. |
Drug: Epacadostat 100 mg
Oral administration
Other Names:
Biological: pembrolizumab 200 mg
Intravenous (IV) infusion
Other Names:
Drug: Carboplatin Area Under the Curve (AUC) 5
IV infusion
Other Names:
Drug: Pemetrexed 500 mg/m^2
IV infusion
Other Names:
|
| Experimental: Part B Cohort 3: pembrolizumab+carboplatin+paclitaxel For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and 100 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years). For the first 4 cycles, participants also received a one-time IV infusion of AUC 6 carboplatin and 200 mg/m^2 paclitaxel on Day 1. Treatment with epacadostat was stopped with protocol amendment 02. |
Drug: Epacadostat 100 mg
Oral administration
Other Names:
Biological: pembrolizumab 200 mg
Intravenous (IV) infusion
Other Names:
Drug: Paclitaxel 200 mg/m^2
IV infusion
Other Names:
Drug: Carboplatin AUC 6
IV infusion
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (NCI-CTCAE v.4.0) [Up to Day 7 for Part A Cohort 1; up to Day 21 for Part A Cohort 2 and Part B]
A DLT was defined as the occurrence of any treatment-emergent adverse event occurring up to and including Study Day 7 for Part A Cohort 1 or Day 21 for Part A Cohort 2 and Part B. The following criteria defined DLTs: Grade (G) 4 thrombocytopenia; G4 neutropenia (despite optimal supportive care in Part B) lasting >1 week; febrile neutropenia (only if considered clinically significant in Part B); G4 toxicity; G3 laboratory abnormality lasting >1 week: G3 toxicity excluding nausea or vomiting controlled within 72 hours, rash in the absence of desquamation, no mucosal involvement, does not require systemic steroids, and resolves to G1 by the next scheduled dose of pembrolizumab or 14 days; G2 or higher episcleritis, uveitis, or iritis; unable to receive 75% of epacadostat or 1 dose of pembrolizumab during the DLT observation period because of toxicity, even if the toxicity does not meet DLT criteria; or >2 week delay in initiating Cycle 2 due to toxicity.
- Number of Participants Who Experienced At Least One Adverse Event (AE) [Up to approximately 39.7 months]
An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event. The number of participants who experienced an AE was reported for each arm.
- Number of Participants Who Discontinued Study Treatment Due to An Adverse Event (AE) [Up to approximately 38.5 months]
An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event. The number of participants who discontinued due to an AE was reported for each arm.
Secondary Outcome Measures
- Maximum Concentration (Cmax) of Epacadostat in Part A [Cycle 1 (28-day cycle): Days 1, 5, and 12 at predose and 0.5, 1, 2, 4, 6, 8 and 10 hours postdose]
Cmax was the maximum observed concentration of epacadostat in plasma for epacadostat administered alone (Cohort 1) and epacadostat administered with pembrolizumab (Cohort 2). Per protocol, Cmax for Cohort 1 was measured on Days 1, 5, and 12 and Cmax for Cohort 2 was measured on Day 5 only. Blood samples were collected pre-dose and post-dose at multiple time points up to 12 days during Cycle 1 (28-day cycle). Cmax is presented as a geometric mean with a percent geometric coefficient of variation.
- Time to Maximum Concentration (Tmax) of Epacadostat in Part A [Cycle 1 (28-day cycle): Days 1, 5, and 12 at predose and 0.5, 1, 2, 4, 6, 8 and 10 hours postdose]
Tmax was the time required to reach the maximum concentration of epacadostat in plasma for epacadostat administered alone (Cohort 1) and epacadostat administered with pembrolizumab (Cohort 2). Per protocol, Tmax for Cohort 1 was measured on Days 1, 5, and 12 and Tmax for Cohort 2 was measured on Day 5 only. Blood samples were collected pre-dose and post-dose at multiple time points up to 12 days during Cycle 1 (28-day cycle). Tmax is presented as a Median with a full range.
- Area Under the Concentration-Time Curve From Zero to the Time of the Last Measurable Concentration (AUC0-t) of Epacadostat in Part A [Cycle 1 (28-day cycle): Days 1, 5, and 12 at predose and 0.5, 1, 2, 4, 6, 8 and 10 hours postdose]
AUC0-t was defined as the AUC from zero to the time of the last measurable concentration of epacadostat in plasma for epacadostat administered alone (Cohort 1) and epacadostat administered with pembrolizumab (Cohort 2). Per protocol, AUC0-t for Cohort 1 was measured on Days 1, 5, and 12 and AUC0-t for Cohort 2 was measured on Day 5 only. Blood samples were collected pre-dose and post-dose at multiple time points up to 12 days during Cycle 1 (28-day cycle). AUC0-t is presented as a geometric mean with a percent geometric coefficient of variation.
- Trough Concentration (Ctrough) of Epacadostat in Part A [Cycle 1 (28-day cycle): Days 1, 5, and 12 at predose]
Ctrough was the lowest concentration of epacadostat in plasma just before the next dose for epacadostat administered alone (Cohort 1) and epacadostat administered with pembrolizumab (Cohort 2). Per protocol, Ctrough for Cohort 1 was measured on Days 1, 5, and 12 and Ctrough for Cohort 2 was measured on Day 5 only. Blood samples were collected pre-dose at multiple time points up to 12 days during Cycle 1 (28-day cycle). Ctrough is presented as a geometric mean with a percent geometric coefficient of variation.
- Terminal Half-Life (t1/2) of Epacadostat in Part A [Cycle 1 (28-day cycle): Days 1, 5, and 12 at predose and 0.5, 1, 2, 4, 6, 8 and 10 hours postdose]
t1/2 was the time required to divide the epacadostat concentration by two after reaching pseudo-equilibrium. Plasma t1/2 was measured for epacadostat administered alone (Cohort 1) and epacadostat administered with pembrolizumab (Cohort 2). Per protocol, t1/2 for Cohort 1 was measured on Days 1, 5, and 12 and t1/2 for Cohort 2 was measured on Day 5 only. Blood samples were collected pre-dose and post-dose at multiple time points up to 12 days during Cycle 1 (28-day cycle). t1/2 is presented as a geometric mean with a percent geometric coefficient of variation.
- Maximum Concentration (Cmax) of Pembrolizumab in Part A Cycle 1 [Cycle 1 (21-day pembrolizumab treatment cycle starting at Day 8 of Cycle 1): Day 1 predose and postdose within 30 minutes after the end of pembrolizumab infusion]
Cmax was the maximum observed concentration of pembrolizumab in serum for participants that received either dose regimen in Part A for Cohort 1 combined, Cohort 2 combined, and Cohorts 1+2 combined. Per protocol, the analysis for the Cmax of pembrolizumab was performed in Cycle 1 only. Blood samples were collected predose and postdose within 30 minutes post pembrolizumab infusion during Cycle 1 (21-day pembrolizumab treatment cycle starting at Day 8 of Cycle 1). Cmax is presented as a geometric mean with a percent geometric coefficient of variation.
- Maximum Concentration (Cmax) of Pembrolizumab in Part B Cycle 1 [Cycle 1 (21-day pembrolizumab treatment cycle starting at Day 8 of Cycle 1): Day 1 predose and postdose within 30 minutes after the end of pembrolizumab infusion]
Cmax was the maximum observed concentration of pembrolizumab in serum for participants that received either dose regimen in Part B for Cohort 1, Cohort 2, Cohort 3, and Cohorts 1+2+ 3 combined. Per protocol, the analysis for the Cmax of pembrolizumab was performed in Cycle 1 only. Blood samples were collected predose and postdose within 30 minutes post pembrolizumab infusion during Cycle 1 (21-day pembrolizumab treatment cycle starting at Day 8 of Cycle 1). Cmax is presented as a geometric mean with a percent geometric coefficient of variation.
- Trough Concentration (Ctrough) of Pembrolizumab in Part A Cycles 1, 2, 4, 6, and 8 [Predose prior to the Cycles 1, 2, 4, 6, and 8 infusion]
Ctrough was the lowest concentration of pembrolizumab in serum just before the next dose for participants that received either dose regimen in Part A for Cohort 1 combined, Cohort 2 combined, and Cohorts 1+2 combined. Per protocol, blood sampling for Ctrough was taken at predose prior to the Cycle 1, 2, 4, 6, and 8 infusion. Cycle 1 length was 28 days (21-day pembrolizumab treatment cycle starting at Day 8 of Cycle 1). Cycle 2, 4, 6, and 8 length was 21 days. Ctrough is presented as a geometric mean with a percent geometric coefficient of variation.
- Trough Concentration (Ctrough) of Pembrolizumab in Part B Cycles 1, 2, 4, 6, and 8 [Predose prior to the Cycles 1, 2, 4, 6, and 8 infusion]
Ctrough was the lowest concentration of pembrolizumab in serum just before the next dose for participants that received either dose regimen in Part B for Cohort 1, Cohort 2, Cohort 3, and Cohorts 1+2+3 combined. Per protocol, blood sampling for Ctrough was taken at pre-dose prior to the Cycle 1, 2, 4, 6, and 8 infusion. Cycle 1 length was 28 days (21-day pembrolizumab treatment cycle starting at Day 8 of Cycle 1). Cycle 2, 4, 6, and 8 length was 21 days. Ctrough is presented as a geometric mean with a percent geometric coefficient of variation.
Eligibility Criteria
Criteria
Ages Eligible for Study:
20 Years
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
-
For Part A: Has a histologically-confirmed metastatic or locally advanced solid tumor that has failed to respond to standard therapy, progressed despite standard therapy, or for which standard therapy does not exist.
-
For Part B: Has a histologically-confirmed or cytologically confirmed diagnosis of non-small cell lung carcinoma (NSCLC) stage IIIB/IV, be naïve to systemic therapy, and have confirmation that epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK)-directed therapy is not indicated. Cohort 1 and 2 must have a histological or cytological diagnosis of non-squamous cancer.
-
Has at least one measurable lesion by computed tomography or magnetic resonance imaging per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1
-
Has Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
-
Has a life expectancy of ≥3 months
-
Females must not be pregnant (negative urine or serum human chorionic gonadotropin test within 72 hours of study start)
-
Women of childbearing potential and male participants must agree to use adequate contraception during the study through 120 days after the last dose of study medication
-
For Part A: Has provided tissue for programmed cell death ligand 1 (PD-L1)/ Indoleamine 2,3-dioxygenase 1 (IDO1) expression evaluation from an archival tissue sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated. For Part B submission of tissue is optional.
Exclusion Criteria:
-
Has received prior therapy with an anti-Programmed cell death protein (PD)-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) agents (including ipilimumab or any other antibody/drug specifically targeting T-cell co-stimulation or checkpoint pathways), or IDO1 inhibitor
-
Is currently participating or has participated in a study with an investigational compound or device within 4 weeks, or 5 times half-life of the investigational compound, whichever is longer, of initial dosing on this study
-
For Part A: Has had chemotherapy, targeted small molecule therapy, radiotherapy, major surgery, or biological cancer therapy (including monoclonal antibodies) within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to the first dose of study medication, or who has not recovered (≤ Grade 1 or baseline) from adverse events due to a previously administered treatment
-
For Part B: Has received radiotherapy within 7 days of the first dose of trial treatment or radiation therapy to the lung that is >30 Gray (Gy) within 6 months of the first dose of study medication
-
Is expected to require any other form of systemic or localized anti-neoplastic therapy while in study
-
Has active central nervous system (CNS) metastases and/or carcinomatous meningitis
-
Has symptomatic ascites or pleural effusion
-
Has an active autoimmune disease that has required systemic treatment
-
Is receiving systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 1 week prior to the first dose of study medication
-
Has an active infection requiring systemic therapy
-
Has history of (noninfectious) pneumonitis that required systemic steroids or current pneumonitis/interstitial lung disease
-
Has received a live vaccine within 4 weeks prior to the first dose of study medication
-
Has a known hypersensitivity to the components of the trial treatment or another monoclonal antibody
-
For Part B: Has a known sensitivity to any component of cisplatin, carboplatin, paclitaxel, or pemetrexed.
-
For Part B: Is on chronic systemic steroids with the exception of use of bronchodilators, inhaled steroids, or local steroid injections
-
For Part B cohort 1 and 2: Is unable to interrupt aspirin or other nonsteroidal ant-inflammatory drugs (NSAIDs), other than an aspirin dose ≤1.3 g per day, for a 5-day period (8-day period for long-acting agents, such as piroxicam).
-
For Part B cohort 1 and 2: Is unable or unwilling to take folic acid or vitamin B12 supplementation
-
Is Human Immunodeficiency Virus (HIV)-positive (HIV 1/2 antibodies)
-
Has known history of or is positive for active Hepatitis B (Hepatitis B surface antigen reactive) or has active Hepatitis C (Hepatitis C virus ribonucleic acid)
-
Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
-
Is pregnant or breastfeeding, or expecting to conceive or father children during the study through 120 days after the last dose of study medication
-
Has received monoamine oxidase inhibitors (MAOIs) within the 3 weeks before the first dose of study medication
-
Has any history of Serotonin Syndrome after receiving serotonergic drugs
-
Has presence of a gastrointestinal condition that may affect drug absorption
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Merck Sharp & Dohme LLC
Investigators
- Study Director: Medical Director, Merck Sharp & Dohme LLC
Study Documents (Full-Text)
More Information
Publications
None provided.Responsible Party:
Merck Sharp & Dohme LLC
ClinicalTrials.gov Identifier:
NCT02862457
Other Study ID Numbers:
- 3475-434
- MK-3475-434
- 163423
First Posted:
Aug 11, 2016
Last Update Posted:
Aug 19, 2022
Last Verified:
Aug 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Merck Sharp & Dohme LLC
Additional relevant MeSH terms:
Study Results
Participant Flow
| Recruitment Details | |
|---|---|
| Pre-assignment Detail |
| Arm/Group Title | Part A Cohort 1: Epacadostat 25 mg | Part A Cohort 1: Epacadostat 100 mg | Part A Cohort 2: Epacadostat 25 mg+Pembrolizumab | Part A Cohort 2: Epacadostat 100 mg+Pembrolizumab | Part B Cohort 1: Pembrolizumab+Cisplatin+Pemetrexed | Part B Cohort 2: Pembrolizumab+Carboplatin+Pemetrexed | Part B Cohort 3: Pembrolizumab+Carboplatin+Paclitaxel |
|---|---|---|---|---|---|---|---|
| Arm/Group Description | Participants received 25 mg of epacadostat orally twice daily (BID) alone on Days 1-5 of Cycle 1 (28-day cycle) with a washout on Days 6 and 7. On Day 8 participants received a one-time intravenous (IV) infusion of 200 mg pembrolizumab while continuing to receive 25 mg of epacadostat BID on Days 8-28. For each 21-day cycle thereafter, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and received 25 mg of epacadostat BID on Days 1-21 for up to 35 cycles (approximately 2 years). | Participants received 100 mg of epacadostat orally BID alone on Days 1-5 of Cycle 1 (28-day cycle) with a washout on Days 6 and 7. On Day 8 participants received a one-time IV infusion of 200 mg pembrolizumab while continuing to receive 100 mg of epacadostat BID on Days 8-28. For each 21-day cycle thereafter, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and received 100 mg of epacadostat BID on Days 1-21 for up to 35 cycles (approximately 2 years). | For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and received 25 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years). | For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and received 100 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years). | For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and 100 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years). For the first 4 cycles, participants also received a one-time IV infusion of 75 mg/m^2 cisplatin and 500 mg/m^2 pemetrexed on Day 1. Treatment with epacadostat was stopped with protocol amendment 02. | For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and 100 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years). For the first 4 cycles, participants also received a one-time IV infusion of Area Under the Curve (AUC) 5 carboplatin and 500 mg/m^2 pemetrexed on Day 1. Treatment with epacadostat was stopped with protocol amendment 02. | For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and 100 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years). For the first 4 cycles, participants also received a one-time IV infusion of AUC 6 carboplatin and 200 mg/m^2 paclitaxel on Day 1. Treatment with epacadostat was stopped with protocol amendment 02. |
| Period Title: Overall Study | |||||||
| STARTED | 3 | 3 | 3 | 6 | 7 | 6 | 6 |
| COMPLETED | 1 | 0 | 0 | 2 | 7 | 3 | 5 |
| NOT COMPLETED | 2 | 3 | 3 | 4 | 0 | 3 | 1 |
Baseline Characteristics
| Arm/Group Title | Part A Cohort 1: Epacadostat 25 mg | Part A Cohort 1: Epacadostat 100 mg | Part A Cohort 2: Epacadostat 25 mg+Pembrolizumab | Part A Cohort 2: Epacadostat 100 mg+Pembrolizumab | Part B Cohort 1: Pembrolizumab+Cisplatin+Pemetrexed | Part B Cohort 2: Pembrolizumab+Carboplatin+Pemetrexed | Part B Cohort 3: Pembrolizumab+Carboplatin+Paclitaxel | Total |
|---|---|---|---|---|---|---|---|---|
| Arm/Group Description | Participants received 25 mg of epacadostat orally twice daily (BID) alone on Days 1-5 of Cycle 1 (28-day cycle) with a washout on Days 6 and 7. On Day 8 participants received a one-time intravenous (IV) infusion of 200 mg pembrolizumab while continuing to receive 25 mg of epacadostat BID on Days 8-28. For each 21-day cycle thereafter, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and received 25 mg of epacadostat BID on Days 1-21 for up to 35 cycles (approximately 2 years). | Participants received 100 mg of epacadostat orally BID alone on Days 1-5 of Cycle 1 (28-day cycle) with a washout on Days 6 and 7. On Day 8 participants received a one-time IV infusion of 200 mg pembrolizumab while continuing to receive 100 mg of epacadostat BID on Days 8-28. For each 21-day cycle thereafter, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and received 100 mg of epacadostat BID on Days 1-21 for up to 35 cycles (approximately 2 years). | For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and received 25 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years). | For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and received 100 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years). | For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and 100 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years). For the first 4 cycles, participants also received a one-time IV infusion of 75 mg/m^2 cisplatin and 500 mg/m^2 pemetrexed on Day 1. Treatment with epacadostat was stopped with protocol amendment 02. | For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and 100 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years). For the first 4 cycles, participants also received a one-time IV infusion of Area Under the Curve (AUC) 5 carboplatin and 500 mg/m^2 pemetrexed on Day 1. Treatment with epacadostat was stopped with protocol amendment 02. | For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and 100 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years). For the first 4 cycles, participants also received a one-time IV infusion of AUC 6 carboplatin and 200 mg/m^2 paclitaxel on Day 1. Treatment with epacadostat was stopped with protocol amendment 02. | Total of all reporting groups |
| Overall Participants | 3 | 3 | 3 | 6 | 7 | 6 | 6 | 34 |
| Age (years) [Mean (Standard Deviation) ] | ||||||||
| Mean (Standard Deviation) [years] |
63.7
(7.8)
|
71.0
(4.6)
|
62.0
(12.2)
|
67.5
(3.2)
|
57.9
(7.3)
|
68.0
(3.8)
|
61.0
(13.4)
|
63.9
(8.6)
|
| Sex: Female, Male (Count of Participants) | ||||||||
| Female |
2
66.7%
|
2
66.7%
|
2
66.7%
|
1
16.7%
|
1
14.3%
|
3
50%
|
1
16.7%
|
12
35.3%
|
| Male |
1
33.3%
|
1
33.3%
|
1
33.3%
|
5
83.3%
|
6
85.7%
|
3
50%
|
5
83.3%
|
22
64.7%
|
| Ethnicity (NIH/OMB) (Count of Participants) | ||||||||
| Hispanic or Latino |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| Not Hispanic or Latino |
3
100%
|
3
100%
|
3
100%
|
6
100%
|
7
100%
|
6
100%
|
6
100%
|
34
100%
|
| Unknown or Not Reported |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| Race (NIH/OMB) (Count of Participants) | ||||||||
| American Indian or Alaska Native |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| Asian |
3
100%
|
3
100%
|
3
100%
|
6
100%
|
7
100%
|
6
100%
|
6
100%
|
34
100%
|
| Native Hawaiian or Other Pacific Islander |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| Black or African American |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| White |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| More than one race |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| Unknown or Not Reported |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
Outcome Measures
| Title | Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (NCI-CTCAE v.4.0) |
|---|---|
| Description | A DLT was defined as the occurrence of any treatment-emergent adverse event occurring up to and including Study Day 7 for Part A Cohort 1 or Day 21 for Part A Cohort 2 and Part B. The following criteria defined DLTs: Grade (G) 4 thrombocytopenia; G4 neutropenia (despite optimal supportive care in Part B) lasting >1 week; febrile neutropenia (only if considered clinically significant in Part B); G4 toxicity; G3 laboratory abnormality lasting >1 week: G3 toxicity excluding nausea or vomiting controlled within 72 hours, rash in the absence of desquamation, no mucosal involvement, does not require systemic steroids, and resolves to G1 by the next scheduled dose of pembrolizumab or 14 days; G2 or higher episcleritis, uveitis, or iritis; unable to receive 75% of epacadostat or 1 dose of pembrolizumab during the DLT observation period because of toxicity, even if the toxicity does not meet DLT criteria; or >2 week delay in initiating Cycle 2 due to toxicity. |
| Time Frame | Up to Day 7 for Part A Cohort 1; up to Day 21 for Part A Cohort 2 and Part B |
Outcome Measure Data
| Analysis Population Description |
|---|
| All participants in Parts A and B who received ≥1 dose of study treatment and who completed all safety evaluations in the pre-specified time frame for DLT analysis |
| Arm/Group Title | Part A Cohort 1: Epacadostat 25 mg | Part A Cohort 1: Epacadostat 100 mg | Part A Cohort 2: Epacadostat 25 mg+Pembrolizumab | Part A Cohort 2: Epacadostat 100 mg+Pembrolizumab | Part B Cohort 1: Pembrolizumab+Cisplatin+Pemetrexed | Part B Cohort 2: Pembrolizumab+Carboplatin+Pemetrexed | Part B Cohort 3: Pembrolizumab+Carboplatin+Paclitaxel |
|---|---|---|---|---|---|---|---|
| Arm/Group Description | Participants received 25 mg of epacadostat orally twice daily (BID) alone on Days 1-5 of Cycle 1 (28-day cycle) with a washout on Days 6 and 7. On Day 8 participants received a one-time intravenous (IV) infusion of 200 mg pembrolizumab while continuing to receive 25 mg of epacadostat BID on Days 8-28. For each 21-day cycle thereafter, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and received 25 mg of epacadostat BID on Days 1-21 for up to 35 cycles (approximately 2 years). | Participants received 100 mg of epacadostat orally BID alone on Days 1-5 of Cycle 1 (28-day cycle) with a washout on Days 6 and 7. On Day 8 participants received a one-time IV infusion of 200 mg pembrolizumab while continuing to receive 100 mg of epacadostat BID on Days 8-28. For each 21-day cycle thereafter, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and received 100 mg of epacadostat BID on Days 1-21 for up to 35 cycles (approximately 2 years). | For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and received 25 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years). | For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and received 100 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years). | For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and 100 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years). For the first 4 cycles, participants also received a one-time IV infusion of 75 mg/m^2 cisplatin and 500 mg/m^2 pemetrexed on Day 1. Treatment with epacadostat was stopped with protocol amendment 02. | For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and 100 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years). For the first 4 cycles, participants also received a one-time IV infusion of Area Under the Curve (AUC) 5 carboplatin and 500 mg/m^2 pemetrexed on Day 1. Treatment with epacadostat was stopped with protocol amendment 02. | For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and 100 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years). For the first 4 cycles, participants also received a one-time IV infusion of AUC 6 carboplatin and 200 mg/m^2 paclitaxel on Day 1. Treatment with epacadostat was stopped with protocol amendment 02. |
| Measure Participants | 3 | 3 | 3 | 6 | 7 | 6 | 6 |
| Count of Participants [Participants] |
0
0%
|
0
0%
|
0
0%
|
1
16.7%
|
1
14.3%
|
2
33.3%
|
2
33.3%
|
| Title | Number of Participants Who Experienced At Least One Adverse Event (AE) |
|---|---|
| Description | An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event. The number of participants who experienced an AE was reported for each arm. |
| Time Frame | Up to approximately 39.7 months |
Outcome Measure Data
| Analysis Population Description |
|---|
| All participants who received ≥1 dose of study treatment. |
| Arm/Group Title | Part A Cohort 1: Epacadostat 25 mg | Part A Cohort 1: Epacadostat 100 mg | Part A Cohort 2: Epacadostat 25 mg+Pembrolizumab | Part A Cohort 2: Epacadostat 100 mg+Pembrolizumab | Part B Cohort 1: Pembrolizumab+Cisplatin+Pemetrexed | Part B Cohort 2: Pembrolizumab+Carboplatin+Pemetrexed | Part B Cohort 3: Pembrolizumab+Carboplatin+Paclitaxel |
|---|---|---|---|---|---|---|---|
| Arm/Group Description | Participants received 25 mg of epacadostat orally twice daily (BID) alone on Days 1-5 of Cycle 1 (28-day cycle) with a washout on Days 6 and 7. On Day 8 participants received a one-time intravenous (IV) infusion of 200 mg pembrolizumab while continuing to receive 25 mg of epacadostat BID on Days 8-28. For each 21-day cycle thereafter, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and received 25 mg of epacadostat BID on Days 1-21 for up to 35 cycles (approximately 2 years). | Participants received 100 mg of epacadostat orally BID alone on Days 1-5 of Cycle 1 (28-day cycle) with a washout on Days 6 and 7. On Day 8 participants received a one-time IV infusion of 200 mg pembrolizumab while continuing to receive 100 mg of epacadostat BID on Days 8-28. For each 21-day cycle thereafter, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and received 100 mg of epacadostat BID on Days 1-21 for up to 35 cycles (approximately 2 years). | For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and received 25 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years). | For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and received 100 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years). | For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and 100 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years). For the first 4 cycles, participants also received a one-time IV infusion of 75 mg/m^2 cisplatin and 500 mg/m^2 pemetrexed on Day 1. Treatment with epacadostat was stopped with protocol amendment 02. | For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and 100 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years). For the first 4 cycles, participants also received a one-time IV infusion of Area Under the Curve (AUC) 5 carboplatin and 500 mg/m^2 pemetrexed on Day 1. Treatment with epacadostat was stopped with protocol amendment 02. | For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and 100 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years). For the first 4 cycles, participants also received a one-time IV infusion of AUC 6 carboplatin and 200 mg/m^2 paclitaxel on Day 1. Treatment with epacadostat was stopped with protocol amendment 02. |
| Measure Participants | 3 | 3 | 3 | 6 | 7 | 6 | 6 |
| Count of Participants [Participants] |
3
100%
|
2
66.7%
|
3
100%
|
6
100%
|
7
100%
|
6
100%
|
6
100%
|
| Title | Number of Participants Who Discontinued Study Treatment Due to An Adverse Event (AE) |
|---|---|
| Description | An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event. The number of participants who discontinued due to an AE was reported for each arm. |
| Time Frame | Up to approximately 38.5 months |
Outcome Measure Data
| Analysis Population Description |
|---|
| All participants who received ≥1 dose of study treatment. |
| Arm/Group Title | Part A Cohort 1: Epacadostat 25 mg | Part A Cohort 1: Epacadostat 100 mg | Part A Cohort 2: Epacadostat 25 mg+Pembrolizumab | Part A Cohort 2: Epacadostat 100 mg+Pembrolizumab | Part B Cohort 1: Pembrolizumab+Cisplatin+Pemetrexed | Part B Cohort 2: Pembrolizumab+Carboplatin+Pemetrexed | Part B Cohort 3: Pembrolizumab+Carboplatin+Paclitaxel |
|---|---|---|---|---|---|---|---|
| Arm/Group Description | Participants received 25 mg of epacadostat orally twice daily (BID) alone on Days 1-5 of Cycle 1 (28-day cycle) with a washout on Days 6 and 7. On Day 8 participants received a one-time intravenous (IV) infusion of 200 mg pembrolizumab while continuing to receive 25 mg of epacadostat BID on Days 8-28. For each 21-day cycle thereafter, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and received 25 mg of epacadostat BID on Days 1-21 for up to 35 cycles (approximately 2 years). | Participants received 100 mg of epacadostat orally BID alone on Days 1-5 of Cycle 1 (28-day cycle) with a washout on Days 6 and 7. On Day 8 participants received a one-time IV infusion of 200 mg pembrolizumab while continuing to receive 100 mg of epacadostat BID on Days 8-28. For each 21-day cycle thereafter, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and received 100 mg of epacadostat BID on Days 1-21 for up to 35 cycles (approximately 2 years). | For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and received 25 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years). | For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and received 100 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years). | For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and 100 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years). For the first 4 cycles, participants also received a one-time IV infusion of 75 mg/m^2 cisplatin and 500 mg/m^2 pemetrexed on Day 1. Treatment with epacadostat was stopped with protocol amendment 02. | For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and 100 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years). For the first 4 cycles, participants also received a one-time IV infusion of Area Under the Curve (AUC) 5 carboplatin and 500 mg/m^2 pemetrexed on Day 1. Treatment with epacadostat was stopped with protocol amendment 02. | For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and 100 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years). For the first 4 cycles, participants also received a one-time IV infusion of AUC 6 carboplatin and 200 mg/m^2 paclitaxel on Day 1. Treatment with epacadostat was stopped with protocol amendment 02. |
| Measure Participants | 3 | 3 | 3 | 6 | 7 | 6 | 6 |
| Count of Participants [Participants] |
0
0%
|
1
33.3%
|
0
0%
|
1
16.7%
|
0
0%
|
3
50%
|
3
50%
|
| Title | Maximum Concentration (Cmax) of Epacadostat in Part A |
|---|---|
| Description | Cmax was the maximum observed concentration of epacadostat in plasma for epacadostat administered alone (Cohort 1) and epacadostat administered with pembrolizumab (Cohort 2). Per protocol, Cmax for Cohort 1 was measured on Days 1, 5, and 12 and Cmax for Cohort 2 was measured on Day 5 only. Blood samples were collected pre-dose and post-dose at multiple time points up to 12 days during Cycle 1 (28-day cycle). Cmax is presented as a geometric mean with a percent geometric coefficient of variation. |
| Time Frame | Cycle 1 (28-day cycle): Days 1, 5, and 12 at predose and 0.5, 1, 2, 4, 6, 8 and 10 hours postdose |
Outcome Measure Data
| Analysis Population Description |
|---|
| The analysis population consisted of all participants in Part A that contributed blood samples for analysis of Cmax. Per protocol, Cmax was only measured on Day 5 for Part A Cohort 2. |
| Arm/Group Title | Part A Cohort 1: Epacadostat 25 mg | Part A Cohort 1: Epacadostat 100 mg | Part A Cohort 2: Epacadostat 25 mg+Pembrolizumab | Part A Cohort 2: Epacadostat 100 mg+Pembrolizumab |
|---|---|---|---|---|
| Arm/Group Description | Participants received 25 mg of epacadostat orally twice daily (BID) alone on Days 1-5 of Cycle 1 (28-day cycle) with a washout on Days 6 and 7. On Day 8 participants received a one-time intravenous (IV) infusion of 200 mg pembrolizumab while continuing to receive 25 mg of epacadostat BID on Days 8-28. For each 21-day cycle thereafter, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and received 25 mg of epacadostat BID on Days 1-21 for up to 35 cycles (approximately 2 years). | Participants received 100 mg of epacadostat orally BID alone on Days 1-5 of Cycle 1 (28-day cycle) with a washout on Days 6 and 7. On Day 8 participants received a one-time IV infusion of 200 mg pembrolizumab while continuing to receive 100 mg of epacadostat BID on Days 8-28. For each 21-day cycle thereafter, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and received 100 mg of epacadostat BID on Days 1-21 for up to 35 cycles (approximately 2 years). | For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and received 25 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years). | For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and received 100 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years). |
| Measure Participants | 3 | 3 | 3 | 6 |
| Day 1 |
327
(15.9)
|
1060
(19.7)
|
||
| Day 5 |
269
(19.3)
|
1100
(36.8)
|
371
(10.7)
|
852
(74.0)
|
| Day 12 |
294
(43.8)
|
1200
(27.0)
|
| Title | Time to Maximum Concentration (Tmax) of Epacadostat in Part A |
|---|---|
| Description | Tmax was the time required to reach the maximum concentration of epacadostat in plasma for epacadostat administered alone (Cohort 1) and epacadostat administered with pembrolizumab (Cohort 2). Per protocol, Tmax for Cohort 1 was measured on Days 1, 5, and 12 and Tmax for Cohort 2 was measured on Day 5 only. Blood samples were collected pre-dose and post-dose at multiple time points up to 12 days during Cycle 1 (28-day cycle). Tmax is presented as a Median with a full range. |
| Time Frame | Cycle 1 (28-day cycle): Days 1, 5, and 12 at predose and 0.5, 1, 2, 4, 6, 8 and 10 hours postdose |
Outcome Measure Data
| Analysis Population Description |
|---|
| The analysis population consisted of all participants in Part A that contributed blood samples for analysis of Tmax. Per protocol, Tmax was only measured on Day 5 for Part A Cohort 2. |
| Arm/Group Title | Part A Cohort 1: Epacadostat 25 mg | Part A Cohort 1: Epacadostat 100 mg | Part A Cohort 2: Epacadostat 25 mg+Pembrolizumab | Part A Cohort 2: Epacadostat 100 mg+Pembrolizumab |
|---|---|---|---|---|
| Arm/Group Description | Participants received 25 mg of epacadostat orally twice daily (BID) alone on Days 1-5 of Cycle 1 (28-day cycle) with a washout on Days 6 and 7. On Day 8 participants received a one-time intravenous (IV) infusion of 200 mg pembrolizumab while continuing to receive 25 mg of epacadostat BID on Days 8-28. For each 21-day cycle thereafter, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and received 25 mg of epacadostat BID on Days 1-21 for up to 35 cycles (approximately 2 years). | Participants received 100 mg of epacadostat orally BID alone on Days 1-5 of Cycle 1 (28-day cycle) with a washout on Days 6 and 7. On Day 8 participants received a one-time IV infusion of 200 mg pembrolizumab while continuing to receive 100 mg of epacadostat BID on Days 8-28. For each 21-day cycle thereafter, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and received 100 mg of epacadostat BID on Days 1-21 for up to 35 cycles (approximately 2 years). | For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and received 25 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years). | For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and received 100 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years). |
| Measure Participants | 3 | 3 | 3 | 6 |
| Day 1 |
2.00
|
2.00
|
||
| Day 5 |
2.00
|
2.00
|
2.00
|
2.00
|
| Day 12 |
2.00
|
2.00
|
| Title | Area Under the Concentration-Time Curve From Zero to the Time of the Last Measurable Concentration (AUC0-t) of Epacadostat in Part A |
|---|---|
| Description | AUC0-t was defined as the AUC from zero to the time of the last measurable concentration of epacadostat in plasma for epacadostat administered alone (Cohort 1) and epacadostat administered with pembrolizumab (Cohort 2). Per protocol, AUC0-t for Cohort 1 was measured on Days 1, 5, and 12 and AUC0-t for Cohort 2 was measured on Day 5 only. Blood samples were collected pre-dose and post-dose at multiple time points up to 12 days during Cycle 1 (28-day cycle). AUC0-t is presented as a geometric mean with a percent geometric coefficient of variation. |
| Time Frame | Cycle 1 (28-day cycle): Days 1, 5, and 12 at predose and 0.5, 1, 2, 4, 6, 8 and 10 hours postdose |
Outcome Measure Data
| Analysis Population Description |
|---|
| The analysis population consisted of all participants in Part A that contributed blood samples for analysis of AUC 0-t. Per protocol, AUC0-t was only measured on Day 5 for Part A Cohort 2. |
| Arm/Group Title | Part A Cohort 1: Epacadostat 25 mg | Part A Cohort 1: Epacadostat 100 mg | Part A Cohort 2: Epacadostat 25 mg+Pembrolizumab | Part A Cohort 2: Epacadostat 100 mg+Pembrolizumab |
|---|---|---|---|---|
| Arm/Group Description | Participants received 25 mg of epacadostat orally twice daily (BID) alone on Days 1-5 of Cycle 1 (28-day cycle) with a washout on Days 6 and 7. On Day 8 participants received a one-time intravenous (IV) infusion of 200 mg pembrolizumab while continuing to receive 25 mg of epacadostat BID on Days 8-28. For each 21-day cycle thereafter, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and received 25 mg of epacadostat BID on Days 1-21 for up to 35 cycles (approximately 2 years). | Participants received 100 mg of epacadostat orally BID alone on Days 1-5 of Cycle 1 (28-day cycle) with a washout on Days 6 and 7. On Day 8 participants received a one-time IV infusion of 200 mg pembrolizumab while continuing to receive 100 mg of epacadostat BID on Days 8-28. For each 21-day cycle thereafter, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and received 100 mg of epacadostat BID on Days 1-21 for up to 35 cycles (approximately 2 years). | For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and received 25 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years). | For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and received 100 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years). |
| Measure Participants | 3 | 3 | 3 | 6 |
| Day 1 |
855
(13.0)
|
4250
(7.1)
|
||
| Day 5 |
1060
(24.0)
|
4670
(22.7)
|
1260
(8.8)
|
3950
(38.8)
|
| Day 12 |
1020
(27.3)
|
4710
(17.9)
|
| Title | Trough Concentration (Ctrough) of Epacadostat in Part A |
|---|---|
| Description | Ctrough was the lowest concentration of epacadostat in plasma just before the next dose for epacadostat administered alone (Cohort 1) and epacadostat administered with pembrolizumab (Cohort 2). Per protocol, Ctrough for Cohort 1 was measured on Days 1, 5, and 12 and Ctrough for Cohort 2 was measured on Day 5 only. Blood samples were collected pre-dose at multiple time points up to 12 days during Cycle 1 (28-day cycle). Ctrough is presented as a geometric mean with a percent geometric coefficient of variation. |
| Time Frame | Cycle 1 (28-day cycle): Days 1, 5, and 12 at predose |
Outcome Measure Data
| Analysis Population Description |
|---|
| The analysis population consisted of all participants in Part A that contributed blood samples for analysis of Ctrough. Per protocol, Ctrough was only measured on Day 5 for Part A Cohort 2. |
| Arm/Group Title | Part A Cohort 1: Epacadostat 25 mg | Part A Cohort 1: Epacadostat 100 mg | Part A Cohort 2: Epacadostat 25 mg+Pembrolizumab | Part A Cohort 2: Epacadostat 100 mg+Pembrolizumab |
|---|---|---|---|---|
| Arm/Group Description | Participants received 25 mg of epacadostat orally twice daily (BID) alone on Days 1-5 of Cycle 1 (28-day cycle) with a washout on Days 6 and 7. On Day 8 participants received a one-time intravenous (IV) infusion of 200 mg pembrolizumab while continuing to receive 25 mg of epacadostat BID on Days 8-28. For each 21-day cycle thereafter, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and received 25 mg of epacadostat BID on Days 1-21 for up to 35 cycles (approximately 2 years). | Participants received 100 mg of epacadostat orally BID alone on Days 1-5 of Cycle 1 (28-day cycle) with a washout on Days 6 and 7. On Day 8 participants received a one-time IV infusion of 200 mg pembrolizumab while continuing to receive 100 mg of epacadostat BID on Days 8-28. For each 21-day cycle thereafter, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and received 100 mg of epacadostat BID on Days 1-21 for up to 35 cycles (approximately 2 years). | For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and received 25 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years). | For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and received 100 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years). |
| Measure Participants | 3 | 3 | 3 | 6 |
| Day 1 |
NA
(NA)
|
NA
(NA)
|
||
| Day 5 |
NA
(NA)
|
87.7
(21.7)
|
NA
(NA)
|
106.0
(64.1)
|
| Day 12 |
NA
(NA)
|
95.4
(31.8)
|
| Title | Terminal Half-Life (t1/2) of Epacadostat in Part A |
|---|---|
| Description | t1/2 was the time required to divide the epacadostat concentration by two after reaching pseudo-equilibrium. Plasma t1/2 was measured for epacadostat administered alone (Cohort 1) and epacadostat administered with pembrolizumab (Cohort 2). Per protocol, t1/2 for Cohort 1 was measured on Days 1, 5, and 12 and t1/2 for Cohort 2 was measured on Day 5 only. Blood samples were collected pre-dose and post-dose at multiple time points up to 12 days during Cycle 1 (28-day cycle). t1/2 is presented as a geometric mean with a percent geometric coefficient of variation. |
| Time Frame | Cycle 1 (28-day cycle): Days 1, 5, and 12 at predose and 0.5, 1, 2, 4, 6, 8 and 10 hours postdose |
Outcome Measure Data
| Analysis Population Description |
|---|
| The analysis population consisted of all participants in Part A that contributed blood samples for analysis of t1/2. Per protocol, t1/2 was only measured on Day 5 for Part A Cohort 2. |
| Arm/Group Title | Part A Cohort 1: Epacadostat 25 mg | Part A Cohort 1: Epacadostat 100 mg | Part A Cohort 2: Epacadostat 25 mg+Pembrolizumab | Part A Cohort 2: Epacadostat 100 mg+Pembrolizumab |
|---|---|---|---|---|
| Arm/Group Description | Participants received 25 mg of epacadostat orally twice daily (BID) alone on Days 1-5 of Cycle 1 (28-day cycle) with a washout on Days 6 and 7. On Day 8 participants received a one-time intravenous (IV) infusion of 200 mg pembrolizumab while continuing to receive 25 mg of epacadostat BID on Days 8-28. For each 21-day cycle thereafter, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and received 25 mg of epacadostat BID on Days 1-21 for up to 35 cycles (approximately 2 years). | Participants received 100 mg of epacadostat orally BID alone on Days 1-5 of Cycle 1 (28-day cycle) with a washout on Days 6 and 7. On Day 8 participants received a one-time IV infusion of 200 mg pembrolizumab while continuing to receive 100 mg of epacadostat BID on Days 8-28. For each 21-day cycle thereafter, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and received 100 mg of epacadostat BID on Days 1-21 for up to 35 cycles (approximately 2 years). | For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and received 25 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years). | For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and received 100 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years). |
| Measure Participants | 3 | 3 | 3 | 6 |
| Day 1 |
3.94
(NA)
|
2.55
(40.9)
|
||
| Day 5 |
3.01
(70.6)
|
2.82
(45.1)
|
2.62
(9.7)
|
3.77
(21.9)
|
| Day 12 |
4.27
(86.0)
|
2.43
(16.1)
|
| Title | Maximum Concentration (Cmax) of Pembrolizumab in Part A Cycle 1 |
|---|---|
| Description | Cmax was the maximum observed concentration of pembrolizumab in serum for participants that received either dose regimen in Part A for Cohort 1 combined, Cohort 2 combined, and Cohorts 1+2 combined. Per protocol, the analysis for the Cmax of pembrolizumab was performed in Cycle 1 only. Blood samples were collected predose and postdose within 30 minutes post pembrolizumab infusion during Cycle 1 (21-day pembrolizumab treatment cycle starting at Day 8 of Cycle 1). Cmax is presented as a geometric mean with a percent geometric coefficient of variation. |
| Time Frame | Cycle 1 (21-day pembrolizumab treatment cycle starting at Day 8 of Cycle 1): Day 1 predose and postdose within 30 minutes after the end of pembrolizumab infusion |
Outcome Measure Data
| Analysis Population Description |
|---|
| The analysis population consisted of all participants in Part A that contributed blood samples for analysis of Cmax. Per protocol, the Cmax of pembrolizumab for Part A was planned to be measured using data combined for Cohort 1 and Cohort 2 for the 200 mg pembrolizumab dose regimen irrespective of epacadostat dose received. |
| Arm/Group Title | Part A Combined Cohort 1 | Part A Combined Cohort 2 | Part A Combined Cohorts 1 and 2 |
|---|---|---|---|
| Arm/Group Description | All participants who received either dose (25 or 100 mg) of epacadostat orally twice daily (BID) alone on Days 1-5 of Cycle 1 (28-day cycle) with a washout on Days 6 and 7. On Day 8 participants received a one-time intravenous (IV) infusion of 200 mg pembrolizumab while continuing to receive 25 mg of epacadostat BID on Days 8-28. For each 21-day cycle thereafter, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and received either dose (25 or 100 mg) of epacadostat BID on Days 1-21. | All participants who received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and received either dose (25 or 100 mg) of epacadostat orally BID on Days 1-21 for each 21-day cycle. | All participants in Cohorts 1 and 2 combined. |
| Measure Participants | 6 | 9 | 15 |
| Geometric Mean (Geometric Coefficient of Variation) [µg/mL] |
80.0
(12.3)
|
73.8
(25.7)
|
76.2
(21.1)
|
| Title | Maximum Concentration (Cmax) of Pembrolizumab in Part B Cycle 1 |
|---|---|
| Description | Cmax was the maximum observed concentration of pembrolizumab in serum for participants that received either dose regimen in Part B for Cohort 1, Cohort 2, Cohort 3, and Cohorts 1+2+ 3 combined. Per protocol, the analysis for the Cmax of pembrolizumab was performed in Cycle 1 only. Blood samples were collected predose and postdose within 30 minutes post pembrolizumab infusion during Cycle 1 (21-day pembrolizumab treatment cycle starting at Day 8 of Cycle 1). Cmax is presented as a geometric mean with a percent geometric coefficient of variation. |
| Time Frame | Cycle 1 (21-day pembrolizumab treatment cycle starting at Day 8 of Cycle 1): Day 1 predose and postdose within 30 minutes after the end of pembrolizumab infusion |
Outcome Measure Data
| Analysis Population Description |
|---|
| The analysis population consisted of all participants in Part B that contributed blood samples for analysis of Cmax. |
| Arm/Group Title | Part B Cohort 1: Pembrolizumab+Cisplatin+Pemetrexed | Part B Cohort 2: Pembrolizumab+Carboplatin+Pemetrexed | Part B Cohort 3: Pembrolizumab+Carboplatin+Paclitaxel | Part B Combined Cohorts 1, 2, and 3 |
|---|---|---|---|---|
| Arm/Group Description | For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and 100 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years). For the first 4 cycles, participants also received a one-time IV infusion of 75 mg/m^2 cisplatin and 500 mg/m^2 pemetrexed on Day 1. Treatment with epacadostat was stopped with protocol amendment 02. | For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and 100 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years). For the first 4 cycles, participants also received a one-time IV infusion of Area Under the Curve (AUC) 5 carboplatin and 500 mg/m^2 pemetrexed on Day 1. Treatment with epacadostat was stopped with protocol amendment 02. | For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and 100 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years). For the first 4 cycles, participants also received a one-time IV infusion of AUC 6 carboplatin and 200 mg/m^2 paclitaxel on Day 1. Treatment with epacadostat was stopped with protocol amendment 02. | All participants in Cohorts 1, 2, and 3 combined. |
| Measure Participants | 7 | 6 | 6 | 19 |
| Geometric Mean (Geometric Coefficient of Variation) [µg/mL] |
73.8
(25.0)
|
64.3
(32.1)
|
65.3
(22.4)
|
68.0
(26.0)
|
| Title | Trough Concentration (Ctrough) of Pembrolizumab in Part A Cycles 1, 2, 4, 6, and 8 |
|---|---|
| Description | Ctrough was the lowest concentration of pembrolizumab in serum just before the next dose for participants that received either dose regimen in Part A for Cohort 1 combined, Cohort 2 combined, and Cohorts 1+2 combined. Per protocol, blood sampling for Ctrough was taken at predose prior to the Cycle 1, 2, 4, 6, and 8 infusion. Cycle 1 length was 28 days (21-day pembrolizumab treatment cycle starting at Day 8 of Cycle 1). Cycle 2, 4, 6, and 8 length was 21 days. Ctrough is presented as a geometric mean with a percent geometric coefficient of variation. |
| Time Frame | Predose prior to the Cycles 1, 2, 4, 6, and 8 infusion |
Outcome Measure Data
| Analysis Population Description |
|---|
| The analysis population consisted of all participants in Part A that contributed blood samples for analysis of Ctrough. Per protocol, the Ctrough of pembrolizumab for Part A was planned to be measured using data combined for Cohort 1 and Cohort 2 for the 200 mg pembrolizumab dose regimen irrespective of epacadostat dose received. |
| Arm/Group Title | Part A Combined Cohort 1 | Part A Combined Cohort 2 | Part A Combined Cohorts 1 And 2 |
|---|---|---|---|
| Arm/Group Description | All participants who received either dose (25 or 100 mg) of epacadostat orally twice daily (BID) alone on Days 1-5 of Cycle 1 (28-day cycle) with a washout on Days 6 and 7. On Day 8 participants received a one-time intravenous (IV) infusion of 200 mg pembrolizumab while continuing to receive 25 mg of epacadostat BID on Days 8-28. For each 21-day cycle thereafter, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and received either dose (25 or 100 mg) of epacadostat BID on Days 1-21. | All participants who received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and received either dose (25 or 100 mg) of epacadostat orally BID on Days 1-21 for each 21-day cycle. | All participants in Cohorts 1 and 2 combined. |
| Measure Participants | 6 | 9 | 15 |
| Cycle 1 |
NA
(NA)
|
NA
(NA)
|
NA
(NA)
|
| Cycle 2 |
17.3
(26.6)
|
17.9
(33.5)
|
17.6
(29.6)
|
| Cycle 4 |
24.5
(31.3)
|
41.8
(21.1)
|
35.0
(36.0)
|
| Cycle 6 |
28.5
(25.3)
|
51.0
(17.4)
|
39.8
(37.5)
|
| Cycle 8 |
38.2
(NA)
|
47.9
(13.9)
|
45.2
(16.1)
|
| Title | Trough Concentration (Ctrough) of Pembrolizumab in Part B Cycles 1, 2, 4, 6, and 8 |
|---|---|
| Description | Ctrough was the lowest concentration of pembrolizumab in serum just before the next dose for participants that received either dose regimen in Part B for Cohort 1, Cohort 2, Cohort 3, and Cohorts 1+2+3 combined. Per protocol, blood sampling for Ctrough was taken at pre-dose prior to the Cycle 1, 2, 4, 6, and 8 infusion. Cycle 1 length was 28 days (21-day pembrolizumab treatment cycle starting at Day 8 of Cycle 1). Cycle 2, 4, 6, and 8 length was 21 days. Ctrough is presented as a geometric mean with a percent geometric coefficient of variation. |
| Time Frame | Predose prior to the Cycles 1, 2, 4, 6, and 8 infusion |
Outcome Measure Data
| Analysis Population Description |
|---|
| The analysis population consisted of all participants in Part B that contributed blood samples for analysis of Ctrough. |
| Arm/Group Title | Part B Cohort 1: Pembrolizumab+Cisplatin+Pemetrexed | Part B Cohort 2: Pembrolizumab+Carboplatin+Pemetrexed | Part B Cohort 3: Pembrolizumab+Carboplatin+Paclitaxel | Part B Combined Cohorts 1, 2, and 3 |
|---|---|---|---|---|
| Arm/Group Description | For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and 100 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years). For the first 4 cycles, participants also received a one-time IV infusion of 75 mg/m^2 cisplatin and 500 mg/m^2 pemetrexed on Day 1. Treatment with epacadostat was stopped with protocol amendment 02. | For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and 100 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years). For the first 4 cycles, participants also received a one-time IV infusion of Area Under the Curve (AUC) 5 carboplatin and 500 mg/m^2 pemetrexed on Day 1. Treatment with epacadostat was stopped with protocol amendment 02. | For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and 100 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years). For the first 4 cycles, participants also received a one-time IV infusion of AUC 6 carboplatin and 200 mg/m^2 paclitaxel on Day 1. Treatment with epacadostat was stopped with protocol amendment 02. | All participants in Cohorts 1, 2, and 3 combined. |
| Measure Participants | 7 | 6 | 6 | 19 |
| Cycle 1 |
NA
(NA)
|
NA
(NA)
|
NA
(NA)
|
NA
(NA)
|
| Cycle 2 |
16.6
(27.6)
|
17.4
(36.6)
|
8.69
(122)
|
13.3
(73.9)
|
| Cycle 4 |
37.8
(20.2)
|
28.1
(NA)
|
25.4
(25.7)
|
31.5
(28.5)
|
| Cycle 6 |
53.8
(29.5)
|
40.5
(NA)
|
21.5
(130)
|
38.6
(73.5)
|
| Cycle 8 |
65.4
(18.6)
|
52.7
(NA)
|
34.5
(42.9)
|
50.3
(39.6)
|
Adverse Events
| Time Frame | Up to approximately 39.7 months | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adverse Event Reporting Description | The analysis population for adverse events (AEs) and all-cause mortality consisted of all participants who received ≥1 dose of study treatment. Per protocol, disease progression was not considered an AE unless considered related to study treatment. Therefore, Medical Dictionary for Regulatory Activities (MedDRA) preferred terms neoplasm progression, malignant neoplasm progression, and disease progression not related to study treatment and/or did not result in death/hospitalization are excluded. | |||||||||||||
| Arm/Group Title | Part A Cohort 1: Epacadostat 25 mg | Part A Cohort 1: Epacadostat 100 mg | Part A Cohort 2: Epacadostat 25 mg+Pembrolizumab | Part A Cohort 2: Epacadostat 100 mg+Pembrolizumab | Part B Cohort 1: Pembrolizumab+Cisplatin+Pemetrexed | Part B Cohort 2: Pembrolizumab+Carboplatin+Pemetrexed | Part B Cohort 3: Pembrolizumab+Carboplatin+Paclitaxel | |||||||
| Arm/Group Description | Participants received 25 mg of epacadostat orally twice daily (BID) alone on Days 1-5 of Cycle 1 (28-day cycle) with a washout on Days 6 and 7. On Day 8 participants received a one-time intravenous (IV) infusion of 200 mg pembrolizumab while continuing to receive 25 mg of epacadostat BID on Days 8-28. For each 21-day cycle thereafter, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and received 25 mg of epacadostat BID on Days 1-21 for up to 35 cycles (approximately 2 years). | Participants received 100 mg of epacadostat orally BID alone on Days 1-5 of Cycle 1 (28-day cycle) with a washout on Days 6 and 7. On Day 8 participants received a one-time IV infusion of 200 mg pembrolizumab while continuing to receive 100 mg of epacadostat BID on Days 8-28. For each 21-day cycle thereafter, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and received 100 mg of epacadostat BID on Days 1-21 for up to 35 cycles (approximately 2 years). | For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and received 25 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years). | For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and received 100 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years). | For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and 100 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years). For the first 4 cycles, participants also received a one-time IV infusion of 75 mg/m^2 cisplatin and 500 mg/m^2 pemetrexed on Day 1. Treatment with epacadostat was stopped with protocol amendment 02. | For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and 100 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years). For the first 4 cycles, participants also received a one-time IV infusion of Area Under the Curve (AUC) 5 carboplatin and 500 mg/m^2 pemetrexed on Day 1. Treatment with epacadostat was stopped with protocol amendment 02. | For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and 100 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years). For the first 4 cycles, participants also received a one-time IV infusion of AUC 6 carboplatin and 200 mg/m^2 paclitaxel on Day 1. Treatment with epacadostat was stopped with protocol amendment 02. | |||||||
All Cause Mortality |
||||||||||||||
| Part A Cohort 1: Epacadostat 25 mg | Part A Cohort 1: Epacadostat 100 mg | Part A Cohort 2: Epacadostat 25 mg+Pembrolizumab | Part A Cohort 2: Epacadostat 100 mg+Pembrolizumab | Part B Cohort 1: Pembrolizumab+Cisplatin+Pemetrexed | Part B Cohort 2: Pembrolizumab+Carboplatin+Pemetrexed | Part B Cohort 3: Pembrolizumab+Carboplatin+Paclitaxel | ||||||||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 1/3 (33.3%) | 3/3 (100%) | 2/3 (66.7%) | 3/6 (50%) | 0/7 (0%) | 2/6 (33.3%) | 1/6 (16.7%) | |||||||
Serious Adverse Events |
||||||||||||||
| Part A Cohort 1: Epacadostat 25 mg | Part A Cohort 1: Epacadostat 100 mg | Part A Cohort 2: Epacadostat 25 mg+Pembrolizumab | Part A Cohort 2: Epacadostat 100 mg+Pembrolizumab | Part B Cohort 1: Pembrolizumab+Cisplatin+Pemetrexed | Part B Cohort 2: Pembrolizumab+Carboplatin+Pemetrexed | Part B Cohort 3: Pembrolizumab+Carboplatin+Paclitaxel | ||||||||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 0/3 (0%) | 2/3 (66.7%) | 2/3 (66.7%) | 1/6 (16.7%) | 1/7 (14.3%) | 2/6 (33.3%) | 2/6 (33.3%) | |||||||
| General disorders | ||||||||||||||
| Pyrexia | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 0/7 (0%) | 0 | 0/6 (0%) | 0 | 1/6 (16.7%) | 1 |
| Hepatobiliary disorders | ||||||||||||||
| Liver disorder | 0/3 (0%) | 0 | 1/3 (33.3%) | 1 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 0/7 (0%) | 0 | 0/6 (0%) | 0 | 0/6 (0%) | 0 |
| Immune system disorders | ||||||||||||||
| Anaphylactic reaction | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 0/7 (0%) | 0 | 0/6 (0%) | 0 | 1/6 (16.7%) | 1 |
| Infections and infestations | ||||||||||||||
| Cytomegalovirus colitis | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 0/7 (0%) | 0 | 1/6 (16.7%) | 1 | 0/6 (0%) | 0 |
| Pneumonia | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 1/3 (33.3%) | 1 | 0/6 (0%) | 0 | 0/7 (0%) | 0 | 1/6 (16.7%) | 1 | 1/6 (16.7%) | 1 |
| Injury, poisoning and procedural complications | ||||||||||||||
| Gastroenteritis radiation | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 1/3 (33.3%) | 1 | 0/6 (0%) | 0 | 0/7 (0%) | 0 | 0/6 (0%) | 0 | 0/6 (0%) | 0 |
| Musculoskeletal and connective tissue disorders | ||||||||||||||
| Rhabdomyolysis | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 1/6 (16.7%) | 1 | 0/7 (0%) | 0 | 0/6 (0%) | 0 | 0/6 (0%) | 0 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | ||||||||||||||
| Malignant neoplasm progression | 0/3 (0%) | 0 | 1/3 (33.3%) | 1 | 1/3 (33.3%) | 1 | 1/6 (16.7%) | 1 | 0/7 (0%) | 0 | 0/6 (0%) | 0 | 0/6 (0%) | 0 |
| Skin and subcutaneous tissue disorders | ||||||||||||||
| Rash maculo-papular | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 1/7 (14.3%) | 1 | 1/6 (16.7%) | 1 | 0/6 (0%) | 0 |
Other (Not Including Serious) Adverse Events |
||||||||||||||
| Part A Cohort 1: Epacadostat 25 mg | Part A Cohort 1: Epacadostat 100 mg | Part A Cohort 2: Epacadostat 25 mg+Pembrolizumab | Part A Cohort 2: Epacadostat 100 mg+Pembrolizumab | Part B Cohort 1: Pembrolizumab+Cisplatin+Pemetrexed | Part B Cohort 2: Pembrolizumab+Carboplatin+Pemetrexed | Part B Cohort 3: Pembrolizumab+Carboplatin+Paclitaxel | ||||||||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 3/3 (100%) | 2/3 (66.7%) | 3/3 (100%) | 6/6 (100%) | 7/7 (100%) | 6/6 (100%) | 6/6 (100%) | |||||||
| Blood and lymphatic system disorders | ||||||||||||||
| Anaemia | 1/3 (33.3%) | 1 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 2/6 (33.3%) | 2 | 1/7 (14.3%) | 2 | 3/6 (50%) | 5 | 1/6 (16.7%) | 2 |
| Neutropenia | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 0/7 (0%) | 0 | 0/6 (0%) | 0 | 2/6 (33.3%) | 2 |
| Cardiac disorders | ||||||||||||||
| Atrial fibrillation | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 1/6 (16.7%) | 1 | 0/7 (0%) | 0 | 0/6 (0%) | 0 | 0/6 (0%) | 0 |
| Ear and labyrinth disorders | ||||||||||||||
| Tinnitus | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 1/7 (14.3%) | 1 | 0/6 (0%) | 0 | 0/6 (0%) | 0 |
| Vertigo | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 1/7 (14.3%) | 1 | 0/6 (0%) | 0 | 0/6 (0%) | 0 |
| Endocrine disorders | ||||||||||||||
| Adrenal insufficiency | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 1/7 (14.3%) | 1 | 0/6 (0%) | 0 | 1/6 (16.7%) | 1 |
| Hypothyroidism | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 1/6 (16.7%) | 1 | 0/7 (0%) | 0 | 0/6 (0%) | 0 | 2/6 (33.3%) | 2 |
| Eye disorders | ||||||||||||||
| Dry eye | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 0/7 (0%) | 0 | 1/6 (16.7%) | 1 | 0/6 (0%) | 0 |
| Gastrointestinal disorders | ||||||||||||||
| Abdominal discomfort | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 0/7 (0%) | 0 | 1/6 (16.7%) | 1 | 0/6 (0%) | 0 |
| Abdominal pain upper | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 0/7 (0%) | 0 | 1/6 (16.7%) | 1 | 1/6 (16.7%) | 1 |
| Anal erosion | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 1/7 (14.3%) | 1 | 0/6 (0%) | 0 | 0/6 (0%) | 0 |
| Angular cheilitis | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 1/3 (33.3%) | 1 | 0/6 (0%) | 0 | 0/7 (0%) | 0 | 0/6 (0%) | 0 | 1/6 (16.7%) | 1 |
| Constipation | 1/3 (33.3%) | 2 | 2/3 (66.7%) | 2 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 6/7 (85.7%) | 7 | 5/6 (83.3%) | 5 | 1/6 (16.7%) | 1 |
| Diarrhoea | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 2/3 (66.7%) | 5 | 2/6 (33.3%) | 3 | 1/7 (14.3%) | 1 | 0/6 (0%) | 0 | 0/6 (0%) | 0 |
| Gastritis | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 1/7 (14.3%) | 1 | 0/6 (0%) | 0 | 0/6 (0%) | 0 |
| Haemorrhoidal haemorrhage | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 1/7 (14.3%) | 1 | 0/6 (0%) | 0 | 0/6 (0%) | 0 |
| Nausea | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 1/6 (16.7%) | 1 | 4/7 (57.1%) | 8 | 5/6 (83.3%) | 8 | 2/6 (33.3%) | 6 |
| Periodontal disease | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 1/7 (14.3%) | 1 | 0/6 (0%) | 0 | 0/6 (0%) | 0 |
| Stomatitis | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 4/7 (57.1%) | 5 | 0/6 (0%) | 0 | 0/6 (0%) | 0 |
| Vomiting | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 1/6 (16.7%) | 1 | 0/7 (0%) | 0 | 1/6 (16.7%) | 1 | 1/6 (16.7%) | 1 |
| General disorders | ||||||||||||||
| Fatigue | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 0/7 (0%) | 0 | 1/6 (16.7%) | 1 | 1/6 (16.7%) | 2 |
| Malaise | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 2/7 (28.6%) | 2 | 1/6 (16.7%) | 1 | 2/6 (33.3%) | 2 |
| Oedema | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 2/7 (28.6%) | 2 | 0/6 (0%) | 0 | 0/6 (0%) | 0 |
| Oedema peripheral | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 1/6 (16.7%) | 1 | 0/7 (0%) | 0 | 0/6 (0%) | 0 | 0/6 (0%) | 0 |
| Pyrexia | 0/3 (0%) | 0 | 1/3 (33.3%) | 1 | 1/3 (33.3%) | 2 | 2/6 (33.3%) | 3 | 4/7 (57.1%) | 4 | 2/6 (33.3%) | 2 | 2/6 (33.3%) | 3 |
| Hepatobiliary disorders | ||||||||||||||
| Hepatic function abnormal | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 1/7 (14.3%) | 1 | 0/6 (0%) | 0 | 0/6 (0%) | 0 |
| Liver disorder | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 1/3 (33.3%) | 1 | 0/6 (0%) | 0 | 0/7 (0%) | 0 | 0/6 (0%) | 0 | 0/6 (0%) | 0 |
| Infections and infestations | ||||||||||||||
| Cystitis | 1/3 (33.3%) | 1 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 0/7 (0%) | 0 | 0/6 (0%) | 0 | 0/6 (0%) | 0 |
| Herpes zoster | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 1/7 (14.3%) | 1 | 0/6 (0%) | 0 | 0/6 (0%) | 0 |
| Nasopharyngitis | 1/3 (33.3%) | 1 | 0/3 (0%) | 0 | 1/3 (33.3%) | 2 | 2/6 (33.3%) | 3 | 0/7 (0%) | 0 | 1/6 (16.7%) | 1 | 0/6 (0%) | 0 |
| Oral candidiasis | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 1/3 (33.3%) | 1 | 0/6 (0%) | 0 | 0/7 (0%) | 0 | 0/6 (0%) | 0 | 0/6 (0%) | 0 |
| Pharyngitis | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 0/7 (0%) | 0 | 1/6 (16.7%) | 1 | 0/6 (0%) | 0 |
| Pneumonia | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 1/7 (14.3%) | 1 | 0/6 (0%) | 0 | 1/6 (16.7%) | 1 |
| Rhinitis | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 1/6 (16.7%) | 1 | 0/7 (0%) | 0 | 0/6 (0%) | 0 | 0/6 (0%) | 0 |
| Tracheitis | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 1/7 (14.3%) | 1 | 0/6 (0%) | 0 | 0/6 (0%) | 0 |
| Upper respiratory tract infection | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 1/6 (16.7%) | 1 | 3/7 (42.9%) | 3 | 0/6 (0%) | 0 | 0/6 (0%) | 0 |
| Injury, poisoning and procedural complications | ||||||||||||||
| Ligament sprain | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 1/3 (33.3%) | 1 | 0/6 (0%) | 0 | 0/7 (0%) | 0 | 0/6 (0%) | 0 | 0/6 (0%) | 0 |
| Limb injury | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 1/7 (14.3%) | 1 | 0/6 (0%) | 0 | 0/6 (0%) | 0 |
| Radiation skin injury | 1/3 (33.3%) | 1 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 0/7 (0%) | 0 | 0/6 (0%) | 0 | 0/6 (0%) | 0 |
| Investigations | ||||||||||||||
| Alanine aminotransferase increased | 1/3 (33.3%) | 1 | 0/3 (0%) | 0 | 1/3 (33.3%) | 2 | 1/6 (16.7%) | 1 | 4/7 (57.1%) | 9 | 2/6 (33.3%) | 2 | 3/6 (50%) | 6 |
| Aspartate aminotransferase increased | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 1/3 (33.3%) | 1 | 1/6 (16.7%) | 1 | 3/7 (42.9%) | 4 | 2/6 (33.3%) | 2 | 3/6 (50%) | 5 |
| Blood alkaline phosphatase increased | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 1/3 (33.3%) | 1 | 0/6 (0%) | 0 | 0/7 (0%) | 0 | 0/6 (0%) | 0 | 1/6 (16.7%) | 1 |
| Blood bilirubin increased | 0/3 (0%) | 0 | 1/3 (33.3%) | 2 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 1/7 (14.3%) | 1 | 0/6 (0%) | 0 | 0/6 (0%) | 0 |
| Blood creatine phosphokinase increased | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 1/6 (16.7%) | 1 | 0/7 (0%) | 0 | 0/6 (0%) | 0 | 0/6 (0%) | 0 |
| Blood creatinine increased | 0/3 (0%) | 0 | 1/3 (33.3%) | 1 | 0/3 (0%) | 0 | 1/6 (16.7%) | 1 | 0/7 (0%) | 0 | 1/6 (16.7%) | 1 | 1/6 (16.7%) | 1 |
| Blood thyroid stimulating hormone decreased | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 0/7 (0%) | 0 | 1/6 (16.7%) | 1 | 0/6 (0%) | 0 |
| Blood thyroid stimulating hormone increased | 1/3 (33.3%) | 1 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 1/6 (16.7%) | 1 | 1/7 (14.3%) | 1 | 0/6 (0%) | 0 | 0/6 (0%) | 0 |
| Electrocardiogram QT prolonged | 1/3 (33.3%) | 1 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 0/7 (0%) | 0 | 0/6 (0%) | 0 | 0/6 (0%) | 0 |
| Gamma-glutamyltransferase increased | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 1/7 (14.3%) | 1 | 0/6 (0%) | 0 | 0/6 (0%) | 0 |
| Haemoglobin decreased | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 1/7 (14.3%) | 1 | 0/6 (0%) | 0 | 0/6 (0%) | 0 |
| Lymphocyte count decreased | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 1/7 (14.3%) | 1 | 0/6 (0%) | 0 | 0/6 (0%) | 0 |
| Neutrophil count decreased | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 1/7 (14.3%) | 9 | 2/6 (33.3%) | 4 | 1/6 (16.7%) | 4 |
| Platelet count decreased | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 0/7 (0%) | 0 | 3/6 (50%) | 3 | 1/6 (16.7%) | 1 |
| White blood cell count decreased | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 1/7 (14.3%) | 9 | 1/6 (16.7%) | 1 | 2/6 (33.3%) | 5 |
| Metabolism and nutrition disorders | ||||||||||||||
| Decreased appetite | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 1/3 (33.3%) | 1 | 0/6 (0%) | 0 | 2/7 (28.6%) | 2 | 3/6 (50%) | 6 | 2/6 (33.3%) | 3 |
| Diabetes mellitus | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 0/7 (0%) | 0 | 0/6 (0%) | 0 | 1/6 (16.7%) | 1 |
| Hyperkalaemia | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 1/7 (14.3%) | 2 | 0/6 (0%) | 0 | 0/6 (0%) | 0 |
| Hypoalbuminaemia | 1/3 (33.3%) | 1 | 0/3 (0%) | 0 | 1/3 (33.3%) | 1 | 2/6 (33.3%) | 2 | 0/7 (0%) | 0 | 0/6 (0%) | 0 | 0/6 (0%) | 0 |
| Hypoglycaemia | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 1/6 (16.7%) | 1 | 0/7 (0%) | 0 | 0/6 (0%) | 0 | 0/6 (0%) | 0 |
| Hypomagnesaemia | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 1/6 (16.7%) | 2 | 0/7 (0%) | 0 | 0/6 (0%) | 0 | 0/6 (0%) | 0 |
| Hyponatraemia | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 1/3 (33.3%) | 2 | 1/6 (16.7%) | 2 | 1/7 (14.3%) | 4 | 0/6 (0%) | 0 | 0/6 (0%) | 0 |
| Musculoskeletal and connective tissue disorders | ||||||||||||||
| Arthralgia | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 0/7 (0%) | 0 | 1/6 (16.7%) | 1 | 3/6 (50%) | 8 |
| Back pain | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 0/7 (0%) | 0 | 1/6 (16.7%) | 1 | 0/6 (0%) | 0 |
| Muscle spasms | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 1/6 (16.7%) | 1 | 0/7 (0%) | 0 | 0/6 (0%) | 0 | 0/6 (0%) | 0 |
| Myalgia | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 1/6 (16.7%) | 1 | 0/7 (0%) | 0 | 0/6 (0%) | 0 | 2/6 (33.3%) | 3 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | ||||||||||||||
| Seborrhoeic keratosis | 1/3 (33.3%) | 1 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 0/7 (0%) | 0 | 0/6 (0%) | 0 | 0/6 (0%) | 0 |
| Tumour pain | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 1/7 (14.3%) | 1 | 0/6 (0%) | 0 | 0/6 (0%) | 0 |
| Nervous system disorders | ||||||||||||||
| Dizziness | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 1/7 (14.3%) | 1 | 0/6 (0%) | 0 | 1/6 (16.7%) | 1 |
| Dysgeusia | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 1/7 (14.3%) | 1 | 2/6 (33.3%) | 2 | 0/6 (0%) | 0 |
| Neuropathy peripheral | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 1/6 (16.7%) | 1 | 0/7 (0%) | 0 | 0/6 (0%) | 0 | 0/6 (0%) | 0 |
| Peripheral sensory neuropathy | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 1/7 (14.3%) | 1 | 0/6 (0%) | 0 | 2/6 (33.3%) | 3 |
| Vagus nerve disorder | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 1/7 (14.3%) | 1 | 0/6 (0%) | 0 | 0/6 (0%) | 0 |
| Psychiatric disorders | ||||||||||||||
| Delirium | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 1/6 (16.7%) | 1 | 0/7 (0%) | 0 | 0/6 (0%) | 0 | 0/6 (0%) | 0 |
| Insomnia | 1/3 (33.3%) | 2 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 1/7 (14.3%) | 1 | 1/6 (16.7%) | 1 | 0/6 (0%) | 0 |
| Renal and urinary disorders | ||||||||||||||
| Pollakiuria | 1/3 (33.3%) | 1 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 0/7 (0%) | 0 | 0/6 (0%) | 0 | 0/6 (0%) | 0 |
| Reproductive system and breast disorders | ||||||||||||||
| Pruritus genital | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 1/7 (14.3%) | 1 | 0/6 (0%) | 0 | 0/6 (0%) | 0 |
| Respiratory, thoracic and mediastinal disorders | ||||||||||||||
| Cough | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 1/7 (14.3%) | 1 | 0/6 (0%) | 0 | 0/6 (0%) | 0 |
| Dysphonia | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 0/7 (0%) | 0 | 1/6 (16.7%) | 1 | 0/6 (0%) | 0 |
| Haemoptysis | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 0/7 (0%) | 0 | 0/6 (0%) | 0 | 1/6 (16.7%) | 1 |
| Hiccups | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 1/7 (14.3%) | 1 | 0/6 (0%) | 0 | 1/6 (16.7%) | 1 |
| Pneumonitis | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 1/3 (33.3%) | 1 | 0/6 (0%) | 0 | 1/7 (14.3%) | 1 | 0/6 (0%) | 0 | 0/6 (0%) | 0 |
| Productive cough | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 1/6 (16.7%) | 1 | 0/7 (0%) | 0 | 0/6 (0%) | 0 | 0/6 (0%) | 0 |
| Skin and subcutaneous tissue disorders | ||||||||||||||
| Alopecia | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 0/7 (0%) | 0 | 0/6 (0%) | 0 | 4/6 (66.7%) | 4 |
| Decubitus ulcer | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 1/6 (16.7%) | 1 | 0/7 (0%) | 0 | 0/6 (0%) | 0 | 0/6 (0%) | 0 |
| Dermatitis acneiform | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 1/7 (14.3%) | 1 | 0/6 (0%) | 0 | 0/6 (0%) | 0 |
| Dry skin | 0/3 (0%) | 0 | 1/3 (33.3%) | 1 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 0/7 (0%) | 0 | 0/6 (0%) | 0 | 0/6 (0%) | 0 |
| Nail ridging | 1/3 (33.3%) | 1 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 0/7 (0%) | 0 | 0/6 (0%) | 0 | 0/6 (0%) | 0 |
| Night sweats | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 1/3 (33.3%) | 1 | 0/6 (0%) | 0 | 0/7 (0%) | 0 | 0/6 (0%) | 0 | 0/6 (0%) | 0 |
| Pruritus | 0/3 (0%) | 0 | 1/3 (33.3%) | 1 | 1/3 (33.3%) | 1 | 1/6 (16.7%) | 1 | 1/7 (14.3%) | 1 | 1/6 (16.7%) | 1 | 1/6 (16.7%) | 1 |
| Purpura | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 0/7 (0%) | 0 | 1/6 (16.7%) | 1 | 0/6 (0%) | 0 |
| Rash | 2/3 (66.7%) | 4 | 0/3 (0%) | 0 | 2/3 (66.7%) | 2 | 2/6 (33.3%) | 2 | 1/7 (14.3%) | 1 | 0/6 (0%) | 0 | 2/6 (33.3%) | 3 |
| Rash maculo-papular | 0/3 (0%) | 0 | 1/3 (33.3%) | 1 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 1/7 (14.3%) | 1 | 2/6 (33.3%) | 3 | 0/6 (0%) | 0 |
| Seborrhoeic dermatitis | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 0/7 (0%) | 0 | 1/6 (16.7%) | 1 | 1/6 (16.7%) | 1 |
| Urticaria | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 2/7 (28.6%) | 2 | 0/6 (0%) | 0 | 1/6 (16.7%) | 1 |
| Vascular disorders | ||||||||||||||
| Hypertension | 0/3 (0%) | 0 | 1/3 (33.3%) | 1 | 1/3 (33.3%) | 1 | 1/6 (16.7%) | 1 | 0/7 (0%) | 0 | 0/6 (0%) | 0 | 0/6 (0%) | 0 |
| Vascular pain | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 0/7 (0%) | 0 | 0/6 (0%) | 0 | 1/6 (16.7%) | 2 |
| Vasculitis | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/3 (0%) | 0 | 0/6 (0%) | 0 | 1/7 (14.3%) | 1 | 0/6 (0%) | 0 | 0/6 (0%) | 0 |
Limitations/Caveats
[Not Specified]
More Information
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.
Results Point of Contact
| Name/Title | Senior Vice President, Global Clinical Development |
|---|---|
| Organization | Merck Sharp & Dohme LLC |
| Phone | 1-800-672-6372 |
| ClinicalTrialsDisclosure@merck.com |
Responsible Party:
Merck Sharp & Dohme LLC
ClinicalTrials.gov Identifier:
NCT02862457
Other Study ID Numbers:
- 3475-434
- MK-3475-434
- 163423
First Posted:
Aug 11, 2016
Last Update Posted:
Aug 19, 2022
Last Verified:
Aug 1, 2022